Evidence map›Paper›PMID 36498812›Full record

ReviewJournal of clinical medicine2022

SARS-CoV-2 Infection and Outcomes in Children with Inflammatory Bowel Diseases: A Systematic Review.

Anastasia Batsiou, Petros Mantzios, Daniele Piovani, Andreas G Tsantes, Paschalia Kopanou Taliaka, Paraskevi Liakou, Nicoletta Iacovidou, Argirios E Tsantes, Stefanos Bonovas, Rozeta Sokou

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Anastasia BatsiouNeonatal Intensive Care Unit, "Agios Panteleimon" General Hospital of Nikea, 18454 Piraeus, Greece.
Petros MantziosDepartment of Internal Medicine, General Hospital of Eastern Achaia, 25100 Aigio, Greece.ORCID 0000-0002-2784-1702
Daniele PiovaniIRCCS Humanitas Research Hospital, 20089 Milan, Italy.
Andreas G TsantesMicrobiology Department, "Saint Savvas" Oncology Hospital, 11522 Athens, Greece.ORCID 0000-0002-3695-0759
Paschalia Kopanou TaliakaNeonatal Intensive Care Unit, "Agios Panteleimon" General Hospital of Nikea, 18454 Piraeus, Greece.
Paraskevi LiakouNeonatal Intensive Care Unit, "Agios Panteleimon" General Hospital of Nikea, 18454 Piraeus, Greece.ORCID 0000-0002-0739-1484
Nicoletta IacovidouNeonatal Department, Aretaieio Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0001-8021-6191
Argirios E TsantesLaboratory of Haematology and Blood Bank Unit, "Attiko" Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Stefanos BonovasIRCCS Humanitas Research Hospital, 20089 Milan, Italy.ORCID 0000-0001-6102-6579
Rozeta SokouNeonatal Intensive Care Unit, "Agios Panteleimon" General Hospital of Nikea, 18454 Piraeus, Greece.ORCID 0000-0002-9972-8901
National and Kapodistrian University of Athens · GRGeneral Hospital of Nikea · GRHumanitas University · ITKAT General Hospital of Attica · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of COVID-19 on pediatric patients with inflammatory bowel disease (PIBD) is still not clear and the knowledge acquired over the last 2 years is still evolving. This study aims to investigate the risk and clinical outcomes of COVID-19 in patients with PIBD. A systematic search of PubMed and Scopus databases was conducted to identify studies published up until September 2022. Out of the 475 articles screened, 14 studies were included in the review. Of the 4006 children with PIBD included, 390 (9.7%) tested positive for COVID-19. Among those with COVID-19, 5.9% (0-16.7%) needed hospitalization, 0.6% (0-1%) were admitted to the pediatric intensive care unit (PICU), and no deaths were reported. Among the included studies, only four presented details regarding patients' symptoms, with 21% (0-25%) presenting gastrointestinal (GI) symptoms. An association between PIBD activity or specific treatment and COVID-19 outcome could not be established. The prevalence of COVID-19 in patients with PIBD was low; therefore, the initial concerns regarding higher infection risk and worse prognosis in this population are not supported by the currently available data. Further research is needed to determine the natural history of the infection and the optimal treatment for these patients. Much is still unclear and additional studies should be performed in order to optimize prevention and care for this special group of patients.

Indexed as

childCOVID-19inflammatory bowel diseasespediatricsSARS-CoV-2

Identifiers

PMID36498812
PMCPMC9737360
OpenAlexW4311285153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.